267 related articles for article (PubMed ID: 15184865)
1. Disease associated mutations at valine 804 in the RET receptor tyrosine kinase confer resistance to selective kinase inhibitors.
Carlomagno F; Guida T; Anaganti S; Vecchio G; Fusco A; Ryan AJ; Billaud M; Santoro M
Oncogene; 2004 Aug; 23(36):6056-63. PubMed ID: 15184865
[TBL] [Abstract][Full Text] [Related]
2. Identification of RET kinase inhibitors as potential new treatment for sporadic and inherited thyroid cancer.
Carlomagno F; Santoro M
J Chemother; 2004 Nov; 16 Suppl 4():49-51. PubMed ID: 15693160
[TBL] [Abstract][Full Text] [Related]
3. ZD6474, an orally available inhibitor of KDR tyrosine kinase activity, efficiently blocks oncogenic RET kinases.
Carlomagno F; Vitagliano D; Guida T; Ciardiello F; Tortora G; Vecchio G; Ryan AJ; Fontanini G; Fusco A; Santoro M
Cancer Res; 2002 Dec; 62(24):7284-90. PubMed ID: 12499271
[TBL] [Abstract][Full Text] [Related]
4. Regulation of p27Kip1 protein levels contributes to mitogenic effects of the RET/PTC kinase in thyroid carcinoma cells.
Vitagliano D; Carlomagno F; Motti ML; Viglietto G; Nikiforov YE; Nikiforova MN; Hershman JM; Ryan AJ; Fusco A; Melillo RM; Santoro M
Cancer Res; 2004 Jun; 64(11):3823-9. PubMed ID: 15172989
[TBL] [Abstract][Full Text] [Related]
5. Efficient inhibition of RET/papillary thyroid carcinoma oncogenic kinases by 4-amino-5-(4-chloro-phenyl)-7-(t-butyl)pyrazolo[3,4-d]pyrimidine (PP2).
Carlomagno F; Vitagliano D; Guida T; Basolo F; Castellone MD; Melillo RM; Fusco A; Santoro M
J Clin Endocrinol Metab; 2003 Apr; 88(4):1897-902. PubMed ID: 12679489
[TBL] [Abstract][Full Text] [Related]
6. The kinase inhibitor PP1 blocks tumorigenesis induced by RET oncogenes.
Carlomagno F; Vitagliano D; Guida T; Napolitano M; Vecchio G; Fusco A; Gazit A; Levitzki A; Santoro M
Cancer Res; 2002 Feb; 62(4):1077-82. PubMed ID: 11861385
[TBL] [Abstract][Full Text] [Related]
7. Oncogenic activation of RET by two distinct FMTC mutations affecting the tyrosine kinase domain.
Pasini A; Geneste O; Legrand P; Schlumberger M; Rossel M; Fournier L; Rudkin BB; Schuffenecker I; Lenoir GM; Billaud M
Oncogene; 1997 Jul; 15(4):393-402. PubMed ID: 9242375
[TBL] [Abstract][Full Text] [Related]
8. ZD6474 suppresses oncogenic RET isoforms in a Drosophila model for type 2 multiple endocrine neoplasia syndromes and papillary thyroid carcinoma.
Vidal M; Wells S; Ryan A; Cagan R
Cancer Res; 2005 May; 65(9):3538-41. PubMed ID: 15867345
[TBL] [Abstract][Full Text] [Related]
9. PP1 inhibitor induces degradation of RETMEN2A and RETMEN2B oncoproteins through proteosomal targeting.
Carniti C; Perego C; Mondellini P; Pierotti MA; Bongarzone I
Cancer Res; 2003 May; 63(9):2234-43. PubMed ID: 12727845
[TBL] [Abstract][Full Text] [Related]
10. A rapid method for the purification of wild-type and V804M mutant ret catalytic domain: A tool to study thyroid cancer.
Sala E; Mologni L; Cazzaniga S; Papinutto E; Gambacorti-Passerini C
Int J Biol Macromol; 2006 Aug; 39(1-3):60-5. PubMed ID: 16490247
[TBL] [Abstract][Full Text] [Related]
11. A GTG to ATG novel point mutation at codon 804 in exon 14 of the RET proto-oncogene in two families affected by familial medullary thyroid carcinoma.
Fattoruso O; Quadro L; Libroia A; Verga U; Lupoli G; Cascone E; Colantuoni V
Hum Mutat; 1998; Suppl 1():S167-71. PubMed ID: 9452077
[No Abstract] [Full Text] [Related]
12. Identification of tyrosine 806 as a molecular determinant of RET kinase sensitivity to ZD6474.
Carlomagno F; Guida T; Anaganti S; Provitera L; Kjaer S; McDonald NQ; Ryan AJ; Santoro M
Endocr Relat Cancer; 2009 Mar; 16(1):233-41. PubMed ID: 19029224
[TBL] [Abstract][Full Text] [Related]
13. The tyrosine kinase inhibitor ZD6474 blocks proliferation of RET mutant medullary thyroid carcinoma cells.
Vitagliano D; De Falco V; Tamburrino A; Coluzzi S; Troncone G; Chiappetta G; Ciardiello F; Tortora G; Fagin JA; Ryan AJ; Carlomagno F; Santoro M
Endocr Relat Cancer; 2011 Feb; 18(1):1-11. PubMed ID: 20943719
[TBL] [Abstract][Full Text] [Related]
14. The oncogenic activity of RET point mutants for follicular thyroid cells may account for the occurrence of papillary thyroid carcinoma in patients affected by familial medullary thyroid carcinoma.
Melillo RM; Cirafici AM; De Falco V; Bellantoni M; Chiappetta G; Fusco A; Carlomagno F; Picascia A; Tramontano D; Tallini G; Santoro M
Am J Pathol; 2004 Aug; 165(2):511-21. PubMed ID: 15277225
[TBL] [Abstract][Full Text] [Related]
15. Only the substitution of methionine 918 with a threonine and not with other residues activates RET transforming potential.
Cirafici AM; Salvatore G; De Vita G; Carlomagno F; Dathan NA; Visconti R; Melillo RM; Fusco A; Santoro M
Endocrinology; 1997 Apr; 138(4):1450-5. PubMed ID: 9075701
[TBL] [Abstract][Full Text] [Related]
16. RET activation in medullary carcinomas.
Pierotti MA; Arighi E; Degl'innocenti D; Borrello MG
Cancer Treat Res; 2004; 122():389-415. PubMed ID: 16209058
[No Abstract] [Full Text] [Related]
17. Biological and biochemical properties of Ret with kinase domain mutations identified in multiple endocrine neoplasia type 2B and familial medullary thyroid carcinoma.
Iwashita T; Kato M; Murakami H; Asai N; Ishiguro Y; Ito S; Iwata Y; Kawai K; Asai M; Kurokawa K; Kajita H; Takahashi M
Oncogene; 1999 Jul; 18(26):3919-22. PubMed ID: 10445857
[TBL] [Abstract][Full Text] [Related]
18. Point mutation of the RET proto-oncogene in the TT human medullary thyroid carcinoma cell line.
Carlomagno F; Salvatore D; Santoro M; de Franciscis V; Quadro L; Panariello L; Colantuoni V; Fusco A
Biochem Biophys Res Commun; 1995 Feb; 207(3):1022-8. PubMed ID: 7864888
[TBL] [Abstract][Full Text] [Related]
19. Development of medullary thyroid carcinoma in transgenic mice expressing the RET protooncogene altered by a multiple endocrine neoplasia type 2A mutation.
Michiels FM; Chappuis S; Caillou B; Pasini A; Talbot M; Monier R; Lenoir GM; Feunteun J; Billaud M
Proc Natl Acad Sci U S A; 1997 Apr; 94(7):3330-5. PubMed ID: 9096393
[TBL] [Abstract][Full Text] [Related]
20. Nuclear factor-kappaB is constitutively active in C-cell carcinoma and required for RET-induced transformation.
Ludwig L; Kessler H; Wagner M; Hoang-Vu C; Dralle H; Adler G; Böhm BO; Schmid RM
Cancer Res; 2001 Jun; 61(11):4526-35. PubMed ID: 11389085
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
